CD8A and neoplasm: Combined inhibitor treatment also significantly increased CD8/Treg ratio compared with olaparib monotherapy and vehicle control groups (Fig. 2b) suggesting that the combined inhibitor treatment can mediate a shift in the tumour microenvironment to one that promotes an anti-tumour immune response.